AstraZeneca Removes Early Degrader and Hematology Programs

Company AstraZeneca Event Type Pipeline removals Modality Androgen-receptor PROTAC; IRAK4 inhibitor Asset AZD9750; AZD2962 (also AZD8359, AZD8421) Target Androgen receptor; IRAK4; STEAP2; CDK2 Disease Area Prostate cancer; hematologic malignancies Summary AstraZeneca’s pipeline updated 30 October lists AZD9750, an androgen-receptor PROTAC for prostate cancer, and AZD2962,…